Excited to share our new publication in AJH: “Impact of Cytogenetic Response to Therapy on Long-Term Survival in AML” Grateful to work with an amazing Cleveland Clinic team under the mentorship of Dr. Moaath Mustafa Ali. 🔗 doi.org/10.1002/ajh.70… #AML #HemeOnc #Leukemia #CCFC

Honored to have 4 abstracts accepted at #ACG2025 — 2 oral, 2 posters! As a resident passionate about HemOnc, I’ve found that collaborating across specialities (GI, Endo, Cards, Primary Care) brings the most impactful ideas. I am grateful for a stellar team! 🙌 Fairview IMRP

🥳 Excited to share our latest publication in the American Journal of Hematology, led by my outstanding mentee John Hanna, MD! 🧬 We are the first to propose formal criteria for cytogenetic response in AML. 📢 Calling on my fellow leukemia specialists: we invite you to validate

From #ENDO2025: #Osteoporosis treatment following #FragilityFracture was associated with significantly reduced #hospitalization and mortality risks among patients aged 80 years and older. Endocrine Society Moathalbliwi Asfand Yar Cheema , MD Aravinthan Vignarajah endocrinologyadvisor.com/reports/osteop…

🚨 Just Submitted my #GIFellowship application! 💩 From Egypt to Houston to Cleveland, thankful for the journey. Grateful for my mentors. You’re my heros. Dedicated to advancing equitable care for liver patients. 📌AAMC ID: 13695481 🩺 Excited for what’s ahead! 💡 #ERAS2025

Honored to see our #ASCO25 abstract featured by エアリオ@モナリザ福岡2日目. These findings challenge long-held assumptions and open new doors in understanding the “obesity paradox” in immunotherapy outcomes. Grateful for the opportunity to contribute. Moaath Mustafa Ali, MD, MPH | د. معاذ مصطفى علي #Immunotherapy #BMI

Outstanding candidate with a strong track record. Highly recommended! Moathalbliwi

Precemtabart tocentecan, an anti-CEACAM5 ADC, is active in heavily pretreated metastatic colorectal cancer—median PFS is 6.9 months, and 72% disease control at 12 weeks. First CRC cohort reported in Nature Medicine. #crcsm

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma rdcu.be/ey3cf

New in Blood Cancer Journal 📢 We analyzed AE profiles of BCMA vs GPRC5D/FcRH5 bispecifics in 2,300+ MM patients across 22 trials. 🧪 Insights to guide safer myeloma care. nature.com/articles/s4140… #MultipleMyeloma #BispecificAntibodies Faiz Anwer MD, thank you for the mentorship

Thrilled to share my first-author publication in CLML! 🚨 📖 Comparative Outcomes of Intensive Chemotherapy vs Venetoclax + HMA in AML patients aged 60–75: A Propensity Score–Adjusted Cohort Study Moaath Mustafa Ali, MD, MPH | د. معاذ مصطفى علي 👉 sciencedirect.com/science/articl… #AML #Leukemia #Hematology #Oncology

🎉🎉 Please join me to congratulate my fantastic mentee Moathalbliwi and research team, who worked hard to conduct this nicely designed study !! Moathalbliwi is applying to Hematology/ Oncology fellowship and deserves all the attention and support her can get !! 🎉🎉

Honored to receive a Reviewer Certificate from Scientific Reports (Springer Nature) for my contribution in 2025. Grateful for the chance to support the peer-review process and advance science in #Hematology #Oncology #PeerReview #ScientificReports

Hi #MedTwitter! I’m Forat, a US-IMG from Jordan 🇯🇴 and applying to #InternalMedicine for #Match2026. I am drawn to intellectual depth and complexity of Internal Medicine. I enjoy watching Real madrid, playing snooker, and mentoring people. AAMC ID: 15929273 Let’s connect !

From Tracking a Bitcoin Chart to Crafting a Differential Diagnosis.🩺📈 Mustafa here! I'm a Non-US IMG from Jordan 🇯🇴 applying to #InternalMedicine residency for #Match2026. In my free time, I enjoy trading & analyzing crypto 📊, cheering on Barcelona & Al-Hussein Irbid ⚽️,

Moathalbliwi We would like to inform you that your post has been published on Hemostasis Today. Thank you for sharing. hemostasistoday.com/voices/moath-a…